156 related articles for article (PubMed ID: 21875154)
1. Molecular modeling studies of Yersinia pestis dihydrofolate reductase.
Oliveira AA; Rennó MN; de Matos CA; Bertuzzi MD; Ramalho TC; Fraga CA; França TC
J Biomol Struct Dyn; 2011 Oct; 29(2):351-67. PubMed ID: 21875154
[TBL] [Abstract][Full Text] [Related]
2. Virtual screening, docking, and dynamics of potential new inhibitors of dihydrofolate reductase from Yersinia pestis.
Bastos Lda C; de Souza FR; Guimarães AP; Sirouspour M; Cuya Guizado TR; Forgione P; Ramalho TC; França TC
J Biomol Struct Dyn; 2016 Oct; 34(10):2184-98. PubMed ID: 26494420
[TBL] [Abstract][Full Text] [Related]
3. Investigating the selectivity of potential new inhibitors of dihydrofolate reductase from Yersinia pestis designed by molecular modeling.
Bastos LDC; de Souza FR; Pereira Souza LM; Forgione P; Cuya T; de Alencastro RB; Pimentel AS; Celmar Costa França T
J Biomol Struct Dyn; 2019 Mar; 37(5):1170-1176. PubMed ID: 29542379
[No Abstract] [Full Text] [Related]
4. Molecular modeling toward selective inhibitors of dihydrofolate reductase from the biological warfare agent Bacillus anthracis.
Giacoppo JO; Mancini DT; Guimarães AP; Gonçalves AS; da Cunha EF; França TC; Ramalho TC
Eur J Med Chem; 2015 Feb; 91():63-71. PubMed ID: 24985033
[TBL] [Abstract][Full Text] [Related]
5. FlexE: efficient molecular docking considering protein structure variations.
Claussen H; Buning C; Rarey M; Lengauer T
J Mol Biol; 2001 Apr; 308(2):377-95. PubMed ID: 11327774
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Coxiela burnetti dihydrofolate reductase via in silico docking with inhibitors and molecular dynamics simulation.
de Souza FR; Guimarães AP; Cuya T; de Freitas MP; Gonçalves ADS; Forgione P; Costa França TC
J Biomol Struct Dyn; 2017 Oct; 35(13):2975-2986. PubMed ID: 27726597
[TBL] [Abstract][Full Text] [Related]
7. Interactions of 5-deazapteridine derivatives with Mycobacterium tuberculosis and with human dihydrofolate reductases.
da Cunha EF; de Castro Ramalho T; Bicca de Alencastro R; Maia ER
J Biomol Struct Dyn; 2004 Oct; 22(2):119-30. PubMed ID: 15317473
[TBL] [Abstract][Full Text] [Related]
8. Structural analysis of Pla protein from the biological warfare agent Yersinia pestis: docking and molecular dynamics of interactions with the mammalian plasminogen system.
Ruback E; Lobo LA; França TC; Pascutti PG
J Biomol Struct Dyn; 2013; 31(5):477-84. PubMed ID: 22881127
[TBL] [Abstract][Full Text] [Related]
9. Towards in silico lead optimization: scores from ensembles of protein/ligand conformations reliably correlate with biological activity.
Popov VM; Yee WA; Anderson AC
Proteins; 2007 Feb; 66(2):375-87. PubMed ID: 17078091
[TBL] [Abstract][Full Text] [Related]
10. Characterization and comparative studies of zebrafish and human recombinant dihydrofolate reductases--inhibition by folic acid and polyphenols.
Kao TT; Wang KC; Chang WN; Lin CY; Chen BH; Wu HL; Shi GY; Tsai JN; Fu TF
Drug Metab Dispos; 2008 Mar; 36(3):508-16. PubMed ID: 18056255
[TBL] [Abstract][Full Text] [Related]
11. Protein flexibility and species specificity in structure-based drug discovery: dihydrofolate reductase as a test system.
Bowman AL; Lerner MG; Carlson HA
J Am Chem Soc; 2007 Mar; 129(12):3634-40. PubMed ID: 17335207
[TBL] [Abstract][Full Text] [Related]
12. Fragment-based design of symmetrical bis-benzimidazoles as selective inhibitors of the trimethoprim-resistant, type II R67 dihydrofolate reductase.
Bastien D; Ebert MC; Forge D; Toulouse J; Kadnikova N; Perron F; Mayence A; Huang TL; Vanden Eynde JJ; Pelletier JN
J Med Chem; 2012 Apr; 55(7):3182-92. PubMed ID: 22424148
[TBL] [Abstract][Full Text] [Related]
13. Structures of dihydrofolate reductase-thymidylate synthase of Trypanosoma cruzi in the folate-free state and in complex with two antifolate drugs, trimetrexate and methotrexate.
Senkovich O; Schormann N; Chattopadhyay D
Acta Crystallogr D Biol Crystallogr; 2009 Jul; 65(Pt 7):704-16. PubMed ID: 19564691
[TBL] [Abstract][Full Text] [Related]
14. Homology modeling of dihydrofolate reductase from T. gondii bonded to antagonists: molecular docking and molecular dynamics simulations.
Pacheco Homem D; Flores R; Tosqui P; de Castro Rozada T; Abicht Basso E; Gasparotto A; Augusto Vicente Seixas F
Mol Biosyst; 2013 Jun; 9(6):1308-15. PubMed ID: 23450239
[TBL] [Abstract][Full Text] [Related]
15. In silico screening against wild-type and mutant Plasmodium falciparum dihydrofolate reductase.
Fogel GB; Cheung M; Pittman E; Hecht D
J Mol Graph Model; 2008 Apr; 26(7):1145-52. PubMed ID: 18037315
[TBL] [Abstract][Full Text] [Related]
16. Identification of potential drug targets in Yersinia pestis using metabolic pathway analysis: MurE ligase as a case study.
Sharma A; Pan A
Eur J Med Chem; 2012 Nov; 57():185-95. PubMed ID: 23059547
[TBL] [Abstract][Full Text] [Related]
17. Specificity in structure-based drug design: identification of a novel, selective inhibitor of Pneumocystis carinii dihydrofolate reductase.
Gschwend DA; Sirawaraporn W; Santi DV; Kuntz ID
Proteins; 1997 Sep; 29(1):59-67. PubMed ID: 9294866
[TBL] [Abstract][Full Text] [Related]
18. The crystal structure of dihydrofolate reductase from Thermotoga maritima: molecular features of thermostability.
Dams T; Auerbach G; Bader G; Jacob U; Ploom T; Huber R; Jaenicke R
J Mol Biol; 2000 Mar; 297(3):659-72. PubMed ID: 10731419
[TBL] [Abstract][Full Text] [Related]
19. Probing the structure of Leishmania donovani chagasi DHFR-TS: comparative protein modeling and protein-ligand interaction studies.
Maganti L; Manoharan P; Ghoshal N
J Mol Model; 2010 Sep; 16(9):1539-47. PubMed ID: 20174846
[TBL] [Abstract][Full Text] [Related]
20. Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs.
Li R; Sirawaraporn R; Chitnumsub P; Sirawaraporn W; Wooden J; Athappilly F; Turley S; Hol WG
J Mol Biol; 2000 Jan; 295(2):307-23. PubMed ID: 10623528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
